| External factors: | Dehydroleucodine |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Cancer |
| Experiment: | MTT assay//Cell Cell proliferation assays//Western blot//SA-β-gal activity assay//Flow cytometry |
| Description: | HeLa and MCF-7 cells were treated with various concentrations of DhL for 72 h, and the effect on cell growth was evaluated by cell counting. The half maximal inhibitory concentration (IC50) of DhL at 72 h culture for HeLa cells was 10 mM. The cell number further decreased to 80% when 20 mM DhL was used. The IC50 of DhL at 72 h culture for MCF-7 cells was 5 mM. Similar effects were observed when DhL was added to synchronized HeLa cells and cell proliferation was assessed by cell count or by MTT assay.The time that cells spent in mitosis was also altered by DhL treatment. Control cells spent an average of 1.960.1 h in mitosis, whereas DhL-treated cells remained in mitosis an average of 4.8 h longer.The concentration of cyclin B1 was significantly lower in treated cells, consistently with the slow progression through the G2/M phase. |
| Regulatory pathway: | p53-p21 |
| R-EF-Pathway: | Upregulation |
| Official symbol(s): | TP53-CDKN1A |
| Pathway experiment: | Western blot |
| Pathway description: | We observed increased p21 levels following DhL treatment at all times tested, consistently with our results for G1 phase accumulation. We also found a transient increase of p53 up to 16 h. |
Annotation: